Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

NCT00193271 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Docetaxel
DRUG: Estramustine

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]